# Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06060613/  
OnCo record `nct06060613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OBX-115 in melanoma and non-small-cell lung cancer, run by Obsidian Therapeutics, Inc., now recruiting.

## Summary

Safety and Efficacy of OBX-115 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06060613 by Obsidian Therapeutics, Inc., with 208 participants planned, started 2023-10-25 and due to reach its primary completion in 2029-06-30. Interventions recorded: OBX-115.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06060613
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
- Sponsor: Obsidian Therapeutics, Inc.
- Enrolled: 208

## Sources

- ClinicalTrials.gov NCT06060613: https://clinicaltrials.gov/study/NCT06060613

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Obsidian Therapeutics](https://onco.cc/companies/obsidian-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06060613.json